Understanding Amyloidosis: Current Trials and Innovative Detection Methods

The diagnostic odyssey

Amyloidosis is a rare and complex disease characterized by the abnormal accumulation of amyloid proteins in various tissues and organs. This condition can manifest in several forms, including light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR), each presenting unique challenges in diagnosis and treatment. The burden of Amyloidosis is significant; patients often endure a lengthy and arduous diagnostic journey, with misdiagnosis being common due to the overlapping symptoms with other diseases. Symptoms such as fatigue, weight loss, neuropathy, and heart issues can lead to confusion, delaying the identification of eligible patients for clinical trials. As a result, the true prevalence of the disease is difficult to ascertain, and many patients remain undiagnosed or misdiagnosed for extended periods.

The challenge of identifying eligible patients for clinical trials is exacerbated by the rarity of the disease and the specific criteria required for enrollment in studies. This situation highlights the need for improved methods of patient identification and recruitment in clinical research.

The trial landscape right now

Currently, there are 34 recruiting clinical trials for Amyloidosis, spanning 193 sites across 20 countries. The distribution of trials reflects a diverse global interest in understanding and treating this complex disease. The leading sponsors include prominent institutions such as Mayo Clinic, Alnylam Pharmaceuticals, AstraZeneca, and Brigham and Women's Hospital, each contributing to advancing research in this field.

The phase mix of these trials includes 19 studies with no specified phase, alongside 5 in Phase I, 4 in Phase II, 2 in Phase III, and 2 in Phase IV. This variety indicates a robust pipeline of research aimed at addressing different aspects of Amyloidosis. Notably, studies such as NCT04561518, titled "ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)," sponsored by Alnylam Pharmaceuticals in the United States, highlight the focus on understanding patient experiences and outcomes in this condition. Additionally, NCT04667494, "Ultrasound Therapy In Cardiac Amyloidosis," sponsored by Brigham and Women's Hospital, represents efforts to explore innovative treatment modalities.

How we detect the match

The integration of HL7 and FHIR standards with artificial intelligence (AI) technologies is revolutionizing the way eligible patients for Amyloidosis trials are identified. By utilizing specific FHIR resources such as Condition, Observation, MedicationRequest, and DiagnosticReport, healthcare systems can analyze existing clinical data without the need for manual chart review.

For instance, a computable phenotype can be developed to surface patients who exhibit lab, genetic, and ICD-10 signals indicative of Amyloidosis. This approach allows for a more efficient identification process, leveraging existing electronic health record (EHR) data to pinpoint eligible candidates based on predefined criteria. By automating the identification process, healthcare providers can enhance patient recruitment for clinical trials, ultimately leading to a faster and more accurate diagnosis for those affected by the disease.

Beyond the trial: better care

The integration of HL7/FHIR and AI not only improves patient identification for clinical trials but also plays a crucial role in enhancing overall patient care. By streamlining data access and improving coordination among healthcare providers, these technologies can reduce the diagnostic odyssey that many Amyloidosis patients face. Enhanced monitoring and coordination of care can lead to earlier interventions and better management of symptoms, regardless of whether a patient enrolls in a clinical trial.

Moreover, the ability to track patient progress through integrated systems allows for personalized treatment plans and timely adjustments based on real-time data. This holistic approach to patient care fosters a more supportive environment for individuals navigating the complexities of Amyloidosis.

The takeaway

Amyloidosis remains a challenging disease for both patients and healthcare providers, but advancements in clinical trials and innovative detection methods are paving the way for better outcomes. By leveraging technology to streamline patient identification and enhance care coordination, the healthcare community can improve the journey for those affected by this rare condition.